Lexaria Bioscience Corp. (CSE: LXX, OTC: LXRP, Forum) announced on Thursday that it had entered a definitive asset purchase agreement through its wholly owned subsidiary
Lexaria Canpharm ULC to sell certain non-core, non-pharmaceutical THC-related business assets for gross proceeds of $3.85 million (CAD).
For more on this story, click
here.
Earlier this month, the food science Company outlines its
planned strategic initiatives for 2021, detailing a focus on advancing solutions related to the regulated pharmaceutical and medical market segments where it believes its patented technology will offer the highest value and utility.
FULL DISCLOSURE: Lexaria Bioscience Corp. is a client of Stockhouse Publishing.